Sage Therapeutics, Inc.

NasdaqGM:SAGE Voorraadrapport

Marktkapitalisatie: US$370.1m

Sage Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Sage Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 29.1% en 31.2% per jaar. De winst per aandeel zal naar verwachting groeien met 31.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -91.5% zijn.

Belangrijke informatie

29.1%

Groei van de winst

31.7%

Groei van de winst per aandeel

Biotechs winstgroei27.1%
Inkomstengroei31.2%
Toekomstig rendement op eigen vermogen-91.5%
Dekking van analisten

Good

Laatst bijgewerkt30 Oct 2024

Recente toekomstige groei-updates

Recent updates

Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left

Oct 07

Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge

Aug 30
Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge

Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)

Jul 25

Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price

Jul 13
Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price

Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

May 30

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

May 21
Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Feb 22
Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Feb 15
Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Sizing Up Sage Therapeutics

Jan 22

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Aug 09
Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Feb 22
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Nov 12
An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Oct 14
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Aug 02

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Jun 15
We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Sage Therapeutics: Well-Funded But Uninspiring Data

Mar 24

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Feb 26
We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Sage Therapeutics: Biogen's Backing May See It Through

Jan 04

What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today

Aug 05
What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today

Sage Therapeutics: Showing Upside, But There Are Plenty Of Unknowns

Jul 25

Winst- en omzetgroeiprognoses

NasdaqGM:SAGE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026155-234-82-13318
12/31/202592-286-260-26921
12/31/202443-394-269-26915
9/30/2024106-338-320-320N/A
6/30/202497-446-374-374N/A
3/31/202491-503-425-425N/A
12/31/202386-541-541-541N/A
9/30/202311-656-549-548N/A
6/30/202310-592-532-531N/A
3/31/20239-558-507-506N/A
12/31/20228-533-461-460N/A
9/30/20226-510-432-431N/A
6/30/20226-503-381-381N/A
3/31/20226-484-377-377N/A
12/31/20216-458-379-378N/A
9/30/20211,114642730730N/A
6/30/20211,114666708708N/A
3/31/20211,113637692692N/A
12/31/20201,114606664664N/A
9/30/20207-537-464-463N/A
6/30/20209-612-504-501N/A
3/31/20209-644-520-515N/A
12/31/20197-680-534-529N/A
9/30/20195-670-520-514N/A
6/30/20192-613-470-465N/A
3/31/201991-462-335-332N/A
12/31/201890-373-264-261N/A
9/30/201890-284-221-218N/A
6/30/201890-235N/A-184N/A
3/31/2018N/A-288N/A-243N/A
12/31/2017N/A-270N/A-219N/A
9/30/2017N/A-257N/A-194N/A
6/30/2017N/A-221N/A-179N/A
3/31/2017N/A-185N/A-146N/A
12/31/2016N/A-159N/A-119N/A
9/30/2016N/A-132N/A-103N/A
6/30/2016N/A-118N/A-92N/A
3/31/2016N/A-108N/A-84N/A
12/31/2015N/A-94N/A-71N/A
9/30/2015N/A-78N/A-61N/A
6/30/2015N/A-64N/A-49N/A
3/31/2015N/A-47N/A-36N/A
12/31/2014N/A-36N/A-27N/A
9/30/2014N/A-29N/A-23N/A
6/30/2014N/A-24N/A-21N/A
3/31/2014N/A-21N/A-20N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat SAGE de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat SAGE de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat SAGE de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van SAGE ( 31.2% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van SAGE ( 31.2% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat SAGE binnen 3 jaar verliesgevend zal zijn.


Ontdek groeibedrijven